

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting**

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on September 18th, 2026. The topic for this meeting will be “Type 1 Diabetes and Cardiorenal Outcomes: Informing a Practice Changing Trial”.

DATES: The meeting will be held on September 18th, 2026, from 8:00 a.m. to 4:00 p.m. EDT.

ADDRESSES: This meeting will be hybrid. The meeting will be held at The Hyatt Regency, 7400 Wisconsin Ave, Bethesda, MD and virtually on the Zoom online video conferencing platform. For details, and to register, please go to the event’s page: <https://www.niddk.nih.gov/news/meetings-workshops/2026/dmicc-t1d-cardiorenal-outcomes-informing-practice-changing-trial>.

FOR FURTHER INFORMATION CONTACT: For further information concerning this meeting, including a draft agenda, which will be posted when available, see the DMICC event website <https://www.niddk.nih.gov/news/meetings-workshops/2026/dmicc-t1d-cardiorenal-outcomes-informing-practice-changing-trial> or contact Dr. William Cefalu, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037, Bethesda, MD 20892, telephone: 301-435-1011; email: dmicc@mail.nih.gov.

SUPPLEMENTARY INFORMATION: In accordance with 42 U.S.C.285c-3, the DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The

September 18, 2026 DMICC meeting will focus on “Type 1 Diabetes and Cardiorenal Outcomes: Informing a Practice Changing Trial”.

Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives or organizations should submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the meeting, oral comments will be allowed on a first-come, first-serve basis.

Members of the public who would like to receive email notification about future DMICC meetings can email dmicc@mail.nih.gov.

Dated: July 27, 2026.

Corinne M. Silva,

Deputy Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

[FR Doc. 2026-15296 Filed 7-28-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HOMELAND SECURITY**U.S. Customs and Border Protection****Air Declaration Zone Test: Extension**

AGENCY: U.S. Customs and Border Protection; DHS.

ACTION: General notice.

SUMMARY: This notice announces that U.S. Customs and Border Protection (CBP) is extending the Air Declaration Zone Test for an additional two years. Current CBP regulations require each traveler to provide a CBP officer with an oral or written declaration of all articles brought into the United States. The Air Declaration Zone Test streamlines the processing of travelers who enter the United States at air ports of entry by

allowing a demonstrative initial declaration to separate travelers who do not have items to declare from those who have items to declare and, in some cases, replace the provision of oral or written declarations.

DATES: CBP is extending the Air Declaration Zone Test at participating air terminals through October 16, 2028, unless renewed. CBP will announce any modifications by notice in the **Federal Register**.

ADDRESSES: Written comments concerning program, policy, and technical issues may be submitted at any time during the test period via email to traveler-entry-programs@cbp.dhs.gov. Please use “Comment on Air Declaration Zone Test” in the subject line of the email.

FOR FURTHER INFORMATION CONTACT: Corey Daboin, Admissibility & Passenger Programs, Office of Field Operations, U.S. Customs & Border Protection, at 202-325-1009, or traveler-entry-programs@cbp.dhs.gov.

SUPPLEMENTARY INFORMATION:**I. Background**

Under existing U.S. Customs and Border Protection (CBP) regulations, each traveler¹ entering the United States must provide an oral or written declaration of all articles brought into the United States, to a CBP officer (CBPO). See part 148, subpart B of title 19 of the Code of Federal Regulations (19 CFR part 148, subpart B). There are currently three types of Federal Inspection Services air port of entry (POE) air terminal facilities: standard, modified egress, and baggage first.

At standard air terminal facilities, a traveler is processed by a CBPO at primary inspection to determine whether the traveler may enter the United States. Once cleared for entry, the traveler then proceeds to the baggage area to collect any luggage and subsequently proceeds through the egress area to the facility exit where a CBPO takes an oral declaration from the traveler or collects a written declaration through CBP Form 6059-B, if the traveler completes one. See 19 CFR 148.12, 148.13. The CBPO then determines whether the declaration requires the payment of a duty or if further examination is necessary. If either is required, the CBPO refers the traveler to secondary inspection. Otherwise, the traveler may then exit

¹ For the purposes of this test, a “traveler” is any individual who is subject to the declaration requirements found in 19 CFR part 148 subpart B. Crewmembers, subject to the declaration requirements found in 19 CFR part 148 subpart G, are not included within this definition of traveler.